Merck KGaA (OTCMKTS:MKKGY) Announces Quarterly Earnings Results

Merck KGaA (OTCMKTS:MKKGY) announced its quarterly earnings results on Thursday. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.26), Zacks reports. Merck KGaA had a net margin of 11.20% and a return on equity of 8.10%.

Merck KGaA Price Performance

MKKGY traded down $1.05 on Thursday, reaching $32.79. The company had a trading volume of 61,679 shares, compared to its average volume of 94,316. Merck KGaA has a 52-week low of $23.73 and a 52-week high of $34.19. The company has a market cap of $21.19 billion, a price-to-earnings ratio of 16.90, a P/E/G ratio of 2.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.09 and a current ratio of 1.69. The business has a 50 day simple moving average of $31.71 and a 200 day simple moving average of $30.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MKKGY shares. Zacks Research upgraded Merck KGaA from a “strong sell” rating to a “hold” rating in a research report on Tuesday. UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Six equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Merck KGaA presently has a consensus rating of “Hold”.

Merck KGaA Company Profile

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.